Advertisement

Inflammation Research

, Volume 65, Issue 1, pp 1–11 | Cite as

Macrophage polarization: the link between inflammation and related diseases

  • Samina Bashir
  • Yadhu Sharma
  • Asif Elahi
  • Farah Khan
Review

Abstract

Objective

In the present review, we try to critically evaluate the two faces of the macrophages and their roles in relation to gene alteration in some inflammatory conditions. The pros- and cons of each type of macrophage in immunologic outcomes are discussed.

Introduction

If “Diversity is the rule of nature”, macrophages have proven to be its obedient followers. A cell type that was classically considered to be activated by Interferon-γ, under the influence of TH-1 type of response and a well-accepted warrior of cellular immunity to the intracellular pathogens is not as simple as once considered. Past decade has revolutionized this notion with the advent of TH-2 influenced alternatively activated macrophages, now established as wound repairing and tissue regenerating.

Methods

Literature survey was done to present a detailed study on this macrophage dichotomy and its relevance to immune disorders via expression of some critical genes, nuclear factor kappa-light-chain-enhancer of activated B cells, peroxisome proliferator-activated receptors and SH2-containing inositol-5′-phosphatase 1, highly implicated in a myriad of immunological emergencies like inflammation, insulin resistance, wound healing, cancer, etc.

Conclusion

The evaluation of macrophage dichotomy in these disorders may prove to be the first step towards the formulation of innovative therapeutic approaches.

Keywords

Cytokines Inflammation Insulin resistance Macrophage polarization Obesity Tumour 

Introduction

Low-grade inflammation is considered to be associated with disorders like metabolic syndrome, arthritis, atherosclerosis, etc. thus becoming a focal point for researchers throughout the world. As inflammation is a characteristic of innate immune response, much attention is laid on the cells controlling innate immune response like macrophages, dendritic cells, natural killer cells, etc. and their secreted products. Macrophages, derived from myeloid precursors of bone marrow are the most important culprits of inflammation. They primarily enter the blood as monocytes, and then traverse into the tissue as tissue macrophages, where they adapt to the local tissue and perform specific functions e.g. Kupffer cells in the liver, microglial cells in brain, mesangial cells in the kidney, etc. Macrophages have a quality of transcriptional probability, in response to an inducer, which is gene-autonomous, leading to the diversity of gene expression, by expressing random combinations of thousands of inducible defence genes. It has been reported earlier that many phenotypic differences are shown by recruited macrophages diverging them from the resident tissue macrophages. Although “macrophage activation” is the term commonly used in this scenario, however, the transcriptional profiling analysis shows that these differences depend highly on the recruiting stimulus and the macrophage location. The phenotypic heterogeneity of macrophages generated in vitro underlies the wide array of phenotypes that occur in vivo. Macrophages resident in tissues adapt to their locale, so that they perform functions specific to their local microenvironment [1] e.g. in obese tissue which is closely associated with inflammation, against an earlier perception that they represent activated or inactivated forms of the same macrophage. Fate-mapping studies have demonstrated that the macrophages residing in various tissues are established before birth and maintain themselves throughout the adulthood without replenishment by blood monocytes, however, an inducing stimulus recruits monocytes, the descendants of whom seem to integrate into the resident macrophage environment [2]. Fate-mapping research needs to be carried further to analyze the equivalence (if any) of the progeny of these recruited monocytes to the resident cells of solid tissues.

Macrophages have been observed to occur in the form of two strains M1 (proinflammatory) and M2 (anti-inflammatory) [3]. In a normal tissue, the ratio of M1:M2 macrophages is highly regulated [4]. On inflammation this ratio is changed i.e. elevated. Although M2 macrophages are further subdivided into well-defined forms like the ones induced by IL-13 and IL-4 are classified as M2a, those exposed to agonists of TLR’s and IL-1R is believed to give rise to M2b form and the third form is generated by the exposure to glucocorticoids and IL-10. However, M1 and M2 are considered to be primary lineages with respect to inflammatory innate response and the present attempt is made to throw some light on the importance of macrophage dichotomy through which they regulate the immune response and the effect of this heterogeneity on some of the common immune disorders. Hence we discuss only two extremes M1 and M2 macrophages for trying to draw a differential line between pro and anti-inflammatory innate immune response.

M1 and M2 macrophages: different strains of the same ancestry

When it comes to immunologic responses “macrophages can be called as autonomous acting bodies”. In contrast to the earlier perception that M1 and M2 strains represent stimulated and unstimulated state of macrophages, Fujisaka et al. [4] observed that the two strains belong to two different subpopulations after using specific markers in cell sorting (F4/80; a macrophage marker, CD11c; M1 marker and CD 206; M2 marker) and separating the two sub-populations, thus, changing the earlier opinion and marking the two as separate phenotypes. The separate existence of two phenotypes was further validated when Lumeng et al. [5] observed that obesity leads to polarization of macrophages in the stromal vascular fraction (SVF) of adipose tissue. Figure 1 demonstrates the changes that adipose tissue undergoes on becoming obese. The macrophage strain activated also depends on the stimulus that is received e.g. leishmania infection inverses the ability of macrophages to stimulate a Th2 response instead of Th1 [6] or methylated bovine serum albumin (mBSA)-stimulated macrophages are able to stimulate allogenic T-lymphocytes, while on culture with lipopolysaccharides (LPS) behave differently [7]. Gordon and Taylor [8] showed that the macrophages in tumours resemble alternatively activated ones. This may partly be due to the tissue regenerating property of these macrophages (discussed later in the review).
Fig. 1

With the progression of obesity, there is infiltration of M1 macrophages in adipose tissue leading to activation of various inflammatory pathways which as a result keep the tissue in chronic low-grade inflammatory state

The macrophages present in the inflamed tissue in a high concentration are known as M1 classically activated macrophages, referring to macrophages having undergone cell activation in response to LPS or IFN-gamma [9, 10]. Gene expression profile of M1 macrophages exhibit high levels of pro-inflammatory cytokines like tumour necrosis factor-α (TNF-α), monocyte chemoattractant protein-1 (MCP-1), Interleukin-6 (IL-6) and inducible nitric oxide synthase (iNOS). Macrophages present in relatively high concentration in normal are known as alternatively activated M2 macrophages characteristically expressing high levels of IL-10, YM1, macrophage and granulocyte inducer-form 1(MgI1), arginase-I to name the important ones and are actively involved in tissue remodelling and repair [11, 12]. Macrophages show their effect mostly via their respective cytokines. Apart from these genotypic differences, phenotypically, M1 classically activated macrophages have been observed to be small, less vacuolated and express more MHC II than alternatively activated macrophages. Thus explaining in a lucid way macrophages can be “killer M1” or “healer M2” [9]. M1 macrophages produce nitric oxide (NO) [13] in high concentration, which aids in inflammatory response as it is a potent vasodilator; on the other hand M2 macrophages not only do produce NO in low concentrations, but also secrete high levels of arginase-1, arginine being the common substrate for both arginase and iNOS. NO cause’s tissue damage and inhibits replication while as Arginase-I causes cell healing and proliferation via formation of ornithine [14, 15, 16].

Fundamental cytokine biology lays stress on the pathways followed by cytokines where some of them are upregulated during inflammation and others downregulated. A balance between cytokines is maintained by a balance between their respective macrophage strains which in turn is regulated by a balance between Th1 and Th2 lymphocytes via their respective lymphokines [17]. Studies have shown a link between the cytokines of one macrophage strain to that of another e.g. when transforming growth factor-β1 (TGF-β1), a potent anti-inflammatory cytokine from alternatively activated (M2) macrophages is inhibited by its antibody, IFN-γ significantly stimulates nitric oxide (NO) production [17]. Pro-inflammatory cytokines like IL-6, TNF-α and Interferon-γ (IFN-γ) from classically activated (M1) macrophages upregulate genes like cyclo-oxygenase-2 (COX-2), interstitial nitric oxide synthase (iNOS) and phospholipase A2 which in turn stimulate the synthesis of mediators of inflammation like PAF1, prostaglandin E2 (PGE2), NO, etc. triggering the inflammatory cascade. A balance is maintained when anti-inflammatory cytokines from alternatively activated (M2) macrophages inhibit the cascade keeping the process regulated.

Thus the evidences given above collectively lead to a conclusion that the two strains of macrophages represent two individual sub-populations of varying phenotype and genotype apart from the different functions they perform. Figure 2 shows the flow of signalling that directs the two strains of macrophages and their characteristic markers.
Fig. 2

Different signalling pathways direct the macrophages differentially to act as two separate strains. Some of the characteristic markers of M1 and M2 macrophages are mentioned

Disorders of unregulated macrophage plasticity

Inflammation

Inflammation is an innate immune response elicited due to tissue injury or destruction and serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. It is a highly regulated process which is under continuous check by most of the immune cells and genes, macrophages being the most important part of them. Macrophages are essential for the initiation and resolution of pathogen- or tissue damage-induced inflammation [8]. However, loss of regulation in inflammation due to genetic or environmental interferences may cause a number of disorders.

Obesity

Obesity-associated complications are the widely studied problem which is associated with a state of low-grade inflammation. Obesity alters the metabolism of adipose tissue with an elevation of hormones and fatty acids that lead to the complications. Obese individuals are predisposed to cardiovascular pathologies and type 2 diabetes. Studies on human subcutaneous adipose tissue have shown that the adipose tissue macrophages (ATM’s) differ in their composition from obese overweight individuals to the lean ones, with remodelling of subcutaneous adipose tissue [18] associated with infiltration of classically activated (M1) macrophages. Macrophages can thus be said to have a major role to play in obesity-associated inflammation. MCP-1/CCR-2 pathway is a very crucial step that signals macrophage recruitment into the obese adipose tissue. Macrophage chemoattractant protein-1 (MCP-1) secreted by classically activated (M1) macrophages has hence been associated with the macrophage infiltration into the obese or inflamed adipose tissue [19, 20, 21, 22], showing that the M1 macrophages have a role in the generation of low-grade inflammation in obesity.

Obesity-associated insulin resistance

One of the known complications of obesity is insulin resistance, a disease where the tissues of body become resistant to secreted insulin, which gradually proceeds to ‘the metabolic syndrome’ where insulin resistance is associated with hypertension, acanthosis nigercans, nephropathy, poly-cystic ovary syndrome, etc. Salicylates have been used for treatment of type II diabetes since early times; although at that time their anti-inflammatory properties were not known. Role of TNF-α in inducing insulin resistance has been widely studied, and link between inflammation and insulin resistance elucidated [23, 24]. This revolutionized the concept about the role of adipose tissue in inflammation, as adipose tissue is associated with high levels of IL-6, TNF-α, PAI-1 etc. [25]. Studies have shown that deficiency of TNF-α and iNOS improves insulin sensitivity in obese wild-type mice [26]. Anti-inflammatory therapies and the disruption of proinflammatory genes, such as IκB kinase-β (IKKβ) have shown to improve insulin sensitivity in obese animals [27] with high expressions of JNK and IKK-β in adipose tissue [28, 29]. Examination of the properties of adipose tissue macrophages (ATMs) in obese animals with a focus on the macrophages that are recruited to adipose tissue during high-fat diet exposure, have shown that these cells have unique inflammatory properties [30, 31].

Tumours

An inflammatory component is also observed in a number of tumours for example there is a massive infiltration of immune cells including macrophages [18, 32]. The spleens of lymphoma bearing mice have been shown to have a subset of alternatively activated macrophages [33, 34]. Clinical and experimental evidence has been given that M1 macrophages mostly promote progression of tumours, including metastasis [35]. In >80 % of the cases, the density of macrophages is directly proportional to poor prognosis [36]. Macrophages isolated from tumours have been observed to have similarity to the macrophages found in developing and regenerating tissues [37], since, M1 macrophages are the ones found abundantly in regenerating tissues hence, it can be inferred that M1 macrophages have a progressive role to play in tumours.

Atherosclerosis

Atherosclerosis is now regarded to be a modified type of inflammation where monocyte-derived macrophages have a central role to play [9]. One of the characteristics of the atherosclerotic plaque is the infiltration of chronic inflammatory cells. There are many types of plaques but, inflammation is a part of all the forms [38, 39]. The role of macrophages is so immense that insulin like growth factor-1 (IGF-1), an important monocyte and macrophage chemotactic agent represents one of the most important mediators in the transformation of a stable lesion into an unstable one. Lumeng et al. observed that ApoE (Apoe) gene expression was decreased in the recruited ATMs compared with resident macrophages affecting cholesterol efflux in recruited macrophages, similar to macrophage foam cells formed over fatty streaks in atherosclerosis [5]. Inflammation, insulin resistance and atherosclerosis are so much related that adipokines like leptin and resistin and inflammatory cytokines released by adipose tissue like TNF-α or the agents released in response to their release e.g. CRP are considered to be good markers of cardiovascular condition [40].

Wound healing

Wound healing is another phenomenon known to be effected by the inflammatory state of the body as the wound healing process proceeds via three steps: inflammation, new tissue formation and remodelling [41]. Epidermis and connective tissue participate actively in wound healing. Several cytokines and growth factors enter the circulation following a wound, majority of which are secreted by neutrophils and macrophages [42]. Redd and colleagues [43] observed that PU.1 null mice which are genetically incapable of raising inflammatory response showed less scaring properties than the normal ones. Thus in this scenario also regulation of inflammation can be a significant step towards prohibition of scar forming and quick healing of wounds. Macrophage skewing is an important factor in the process of wound healing. This can be observed as impaired wound healing in absence of M2 cytokines like TGF-β and vascular endothelial growth factor (VEGF) as was observed by Eming et al. [44], getting M2 macrophages to the central stage of the process of wound healing.

Macrophage plasticity and altered gene expression

So far not much is known about the phenotypic differences between various types of macrophages, however, there is a striking difference in the expression of various genes, which leads to a number of physiological consequences and if unchecked to a myriad of pathological conditions. A proper balance needs to be maintained and is maintained under normal conditions but under some circumstances like obesity, infection, etc. the balance is lost further aggravating the problems. There are a number of genes whose expression varies with the macrophage strain activated but, for the lucidity of the review we chose three important genes (NF-κB, SHIP and PPAR’s) to review their role in inflammation, insulin resistance and tumour (Fig. 3) [45, 46, 47, 48, 49, 50, 51, 52, 53].
Fig. 3

Characteristic phenotypic and genotypic differences between M1 and M2 macrophages with respect to various physiological states

Nuclear factor kappa-B (NF-κB)

Each strain of macrophages shows its effect via its respective cytokines which in turn signal the over- or under-expression of the required genes. NF-κB is a well-known, widely studied pro-inflammatory gene expressed highly by classically activated macrophages. The NF-κB pathway is an important mediator of immunity and inflammation, with short-lived responses characteristic of the canonical pathway, controlled by inhibitor of nuclear factor kappa-B kinase alpha (IKKa) activation, and long-lived responses characteristic of the alternative pathway controlled by nuclear factor kappa-B inducing kinase (NIK) activation [54]. NF-κB activation is mainly associated with nuclear translocation of the p50/p65 heterodimer [54]. It has been observed that the macrophages showing tolerance to the endotoxins, action against endotoxins being the important role of NF-κB, express M2 phenotype with impaired expression of M1 functions. P-50 homo dimers are associated with reduced nuclear translocation of NF-κB [55]. Ablation of the NF-κB p50 subunit prevents development of tolerance, assessed by the selective restoration of M1 mediators (e.g. TNF-α and iNOS) and inhibition of M2 cytokines and chemokines, in response to LPS rechallenge [56, 57]. Thus, the activation or inhibition of NF-κB via selective targeting of its p50 subunit may be the important step for macrophage skewing.

NF-κB and insulin resistance

Inflammation is a predominant factor for insulin resistance where NF-κB has a huge role to play as described in this review. An increased M1 macrophage content with elevated nuclear localization of NF-κB and up regulated transcription of its target genes in the adipose tissue is a characteristic in obesity assisted insulin resistance [45, 58, 59]. Relation of NF-κB to the macrophage polarization came into light when it was observed that TNF-α, a well-known pro-inflammatory cytokine secreted by M1 macrophages, causes serine phosphorylation at two N-terminal domains of IKK, causing up regulation of inflammatory factors by nuclear translocation of NF-κB [56]. Inhibition of NF-κB has been observed to reduce the expression of inflammatory markers like IL-6 and suppressor of cytokine signalling-3 (SOCS-3), in the in vitro inflammatory conditions of 3T3-L1 adipocytes exposed to TNF-α [60]. Relatively weak inhibitors of IKKB have been observed to show anti-inflammatory effects [61] and it leads to inhibition of M1 macrophages on infection by negatively interacting with Stat1 pathway. Deletion of IKKb in macrophages leads to the resistance to infection with an increased expression of NOS2, IL-12, and major histocompatibility complex (MHC) class II by macrophages [62] making IKKb a potent insulin sensitization target in future. A number of studies have demonstrated that saturated fatty acids lead to insulin resistance [63] via NF-κB, induced pro-inflammatory cytokines like IL-6, TNF-α [46, 64, 65], thus, fatty acid-induced insulin resistance is reduced by blocking NF-κB activation [66]. Thus by the discussion above, the role of NF-κB in insulin resistance can be summarized as the molecule which has a potential induce to insulin resistance via induction of macrophage polarization to M1 form.

NF-κB and tumour

The role of NF-κB in tumour is immense as its activity is modulated by the tumour suppressors like P53 and alternative reading frame (ARF) and its subunits suppress the expression of tumour suppressor genes [67]. NF-κB came out to be a major tumorogenic transcription factor after analysis of NF-κB1 subunit (P50–P105) [68, 69] showed its homology to a potent transforming oncogene, V-rel [70]. Another subunit, NF-κB2, is constitutively found in B and T cell lymphomas in rearranged and truncated form [71]. Activation of NF-κB in Hodgkins lymphoma is one of its well-known characteristics [72]. Many studies have shown NF-κB to give resistance to a number of cancers, this may partly be due to the varying causes of cancers where some of them are inflammatory in nature and some are not. The role of NF-κB in anti-cancerous activity can be derived from the fact that DNA damage, apart from activating P53 tumour suppressor induces enhanced DNA binding and transcriptional activity of NF-κB [73]. Ryan and colleagues [74] observed that NFκB-P65 was required for P53-dependant apoptosis. Tumour suppressors like ARF can induce association of P65 with histone deacetylase-1 (HDAC1), causing repression of the gene expression [75]. Thus, NF-κB has a central role whenever involved in tumours be it tumour progression or tumour suppression depending on the type of cancer.

SH2 containing inositol-5′-phosphatase 1 (SHIP-1)

SH2-containing inositol-5′-phosphatase 1 is a 145 kDa protein that has been observed to show the property of endotoxin tolerance [76]. The stimuli for action of SHIP-1 are cytokines, growth factors, antibodies, chemokines, and the integrin ligand [77, 78] SHIP-1 is present in mature granulocytes, monocytes/macrophages, mast cells and platelets [79, 80]. It performs a wide variety of functions by reducing mast cell activation and adhesion to fibronectin by reducing extracellular calcium entry and activating NF-κB and certain PKC isoforms [81], activating B cells [77], thrombin- or collagen-induced activation and fibrinogen-induced spreading of platelets [77, 80], neutrophil surveillance [82] and early erythroid colony formation [83]. It was observed by Rauh et al. that SHIP 1 mutant mice produced tenfold less nitric oxide in comparison to wild counterparts [76]. A tolerance to endotoxins can be improved by upregulation of SHIP as it enhances the classical (M1) activation of bone marrow-derived macrophages. Peritoneal and alveolar macrophages from SHIP−/− mice are abundantly M2 skewed in comparison to their wild-type counterparts, possessing impaired LPS-induced NO production, constitutive arginase-I (ArgI) and YM1 levels [83]. Hence, from above discussion it is evident that SHIP-1 has an important role in M1 macrophage function and change in its expression can be associated with the skewing of macrophages.

SHIP-1 and inflammation-associated insulin resistance

Src homology 2-containing inositol-5-phosphatase, SHIP, is a potent inhibitor of the phosphatidylinositol 3-kinase (PI3K) pathway which negatively regulates the lipopolysaccharide (LPS)-induced proinflammatory cytokine and nitric oxide (NO) production. The response of a particular gene to LPS is an important indicator of its role in inflammation and related disorders. Since, the strain of macrophages activated in response to LPS is M1 type, hence, SHIP may be an important gene marker of this phenotype. The production of pro-inflammatory cytokines likes TNF-α and IL-6 is found to be very low in case of SHIP−/− bone marrow macrophages. A 10-fold increase in SHIP protein is observed in response to LPS which shows the essentiality of SHIP-1in response to endotoxins [47] and it also shows the role of SHIP-1 in M1 macrophages as this is the macrophage type involved in combating endotoxins before the development of endotoxin tolerance which is the characteristic of M2 macrophages. PI3K has been shown to negatively regulate the stability of COX2 mRNA in LPS-stimulated human alveolar macrophages [84], the dampening of PI3 K may be the main cause of pulmonary inflammation. The above discussion leads towards a suspicion that SHIP-1 plays a substantial role in inducing inflammation. Although, no substantial data are available on the relationship between SHIP-1 and insulin resistance, however, a number of inflammatory markers like MCP-1 [85] and TNF-α [31] have been associated with insulin resistance, and inflammation is considered to be one of the major pre-requisites for insulin resistance, hence, the role of SHIP-1 in insulin resistance should be analysed in future.

SHIP-1 in tumour

An overflow of alternatively activated macrophages associated with heavy deposits of YM1 crystals is a characteristic of SHIP−/− mice [86, 87]. The dampening of PI3K pathway by hydrolysis of PIP3 to PI2P is a well-studied effect of SHIP-1 [48, 88]. PI3K pathway is quite essential in proliferation, differentiation, survival activation and migration of haematopoietic pathway [88]. The pathway is used by a number of oncogenes like HER 2/Neu, Ras [88, 89] etc. The mutated form of SHIP-1 has been found in a number of leukemias and lymphomas [90, 91, 92, 93, 94, 95]. The presence of a number of isoforms of SHIP adds to the complexity of the study as the isoforms may be playing completely different roles. Holding SHIP responsible for all the tumours can be a misinterpretation as tumours have also got a genetic and physiological variety and the same gene can be anti for one type of cancer and pro for another one.

Peroxisome proliferator-activated receptors (PPAR’s)

These are the nuclear receptors like steroid and thyroid hormone receptors present in endothelial cells [96, 97]. Following their discovery by Issemann and Green [98] PPAR’s opened the gateway to the study of a number of similar receptors which have types and subtypes generated due to differential RNA splicing and alternate promoter use [99] The nuclear hormone receptor peroxisome proliferator-activated receptor γ (PPARγ) is a central switch that regulates the inflammatory potential of macrophages in both adipose tissue and atherosclerotic plaques [100], though widely studied, role of PPAR-γ and its involvement in macrophage polarization remains surrounded by several questions and confusions. In the absence of ligand, nuclear co-repressors bind PPAR/retinoid X receptor heterodimers [101] and are thought to recruit histone deacetylases to downregulate a gene. Free fatty acids, oxidized lipids, eicosanoid and prostaglandin derivatives weakly activate PPARγ [102, 103, 104]. The receptor may respond to an integrated concentration of nutritionally derived fatty acid ligands and that no high-affinity regulatory ligand exists [105]. PPAR-γ-dependent polarization to the M2 phenotype has been observed at the monocyte level, also, activation of macrophage PPAR-γ inhibits the expression of numerous inflammatory mediators [49]. Lazar, reviewed that the expression of PPAR-γ in the vessels colocalizes with CD68-positive macrophages which is a marker for M2 macrophages [105]. The above discussion supports the fact that PPARγ has a role in regulating macrophage plasticity to some extent and its expression is associated with M2 macrophages.

PPAR’s in inflammation-associated Insulin Resistance

PPAR-γ-advancing drug rosiglitazone is used as an Insulin-sensitizing drug worldwide, showing PPAR-γ as an important key to the doorway of treatment of Insulin Resistance. PPARγ inhibits the expression of a wide range of inflammatory mediators [107]. Thiazolidinediones (TZDs) and other PPARγ ligands have been shown to inhibit the secretion of TNF-α and IL-6 (pro-inflammatory cytokines) in PPARγ-deficient macrophages [108]. Some studies suggest that PPAR-γ does not inhibit inflammatory cytokines; however, it enhances the activation of anti-inflammatory ones. Activation of PPARγ induces transcription of several genes and causes effects such as weight gain, increase in low-density lipoprotein cholesterol and plasma volume expansion [109]. Adipocyte-specific genes, such as adiponectin and perilipin, contain response elements for PPARγ in their promoter regions [50, 110, 111] Mice with a macrophage-specific deletion of PPAR-γ have shown impairment in the maturation of alternatively activated M2 macrophages and up regulation of diet-induced obesity, insulin resistance and glucose intolerance. These mice were found to be defective in the in vivo generation of M2 to a similar extent as macrophage-specific IL-4Rα−/− mice or STAT6 null mice which are associated with inflammatory disorders. As a consequence, PPAR-γ induces more resistance to Th2/M2-driven pathologies, such as cutaneous leishmaniasis [112]. PPAR-γ also causes ligand-based transrepression of NFκB [51, 113] which is an important inflammatory gene as discussed above. Thus, the role of PPAR-γ in insulin resistance has been well elucidated in insulin resistant models and shown to reduce macrophage polarization associated insulin resistance i.e. M1 type of classically activated macrophages [102].

PPAR’s in tumour

A dysregulation of the cell cycle leading to cell proliferation is the representation of Cancer cells making the agents that modulate this phenomenon as important chemotherapeutic agents. Among PPAR’s, PPAR-α is a well-known anti-apoptotic receptor [114]. Study conducted by Peters and colleagues [115] revealed that there is an up regulation of proteins like CDK-4 and C-myc in PPAR-α+ mice as compared to PPAR-α mice, increased expression of Cyclin-dependent kinase 4 (CDK-4) and c-myc is a common characteristic of a number of cancers [114]. It also causes the induction of a common factor of colon carcinoma, cyclo-oxygenase-2 (COX-2), in the epithelial cells of colon [116]. The role of PPAR-γ as a tumour promoter or suppressor remains a matter of controversy as on one hand some studies demonstrate PPAR-γ agonists to cause tumour progression in mice [117] and on another hand PPAR-γ agonists improve differentiation in tumour cell lines [118].

Eicosapentaenoic acid (EPA), fatty acid, suspected to have a role in macrophage polarization has been observed to decrease pancreatic cancer via activation of PPAR-γ [114]. A wide array of research has been done on the role of PPAR-γ in cancers [52, 119]. Thus, looking from the PPAR-γ front, it is an important precursor for macrophage polarization towards alternative M2 phenotype which is an anti-inflammatory and regenerative type of macrophage. Before jumping to any conclusions regarding the therapeutic role of PPAR’s in tumour, a wide array of research needs to be conducted on relationship of peroxisome proliferators or their receptors on promotion or attenuation of carcinogenesis and also the type of agonists that may be helpful for the same.

Conclusion

The discussions made in this review confer that macrophage polarization is the triggering effect that regulates the fate of immune response may it be towards inflammation or tissue repair. Understanding the pathway of inflammation is a complex issue which somehow shows its resolution on the state of macrophage involved. The varying types of cytokines secreted by the two types of macrophages show the role of cytokines in regulating immune response while themselves being regulated by macrophages. A number of genes like NFκB, PPAR-γ, SHIP, etc. involved in inflammatory regulative pathways as discussed above show differential expression profiles with the change in macrophage type involved. Insulin resistance, cardiovascular disorders like atherosclerosis, arthritis, etc. long been linked to inflammation, may find their cure if focus is laid on the ways to revert the polarization of macrophages from pro- to anti-inflammatory state. Throwing some light on this issue may be a powerful tool for the treatment of various autoimmune disorders which cause the complications via inflammation. Before giving due credit to the M2 macrophages for their contributions to various pathologies, attention needs to be paid to their role in increasing angiogenesis, neo-vascularisation and other immune deficiency disorders. Thus the research on macrophage polarization must be taken forward to fill some huge lacuna like:
  • The role of SHIP-1 in macrophage polarization in case of tumours has not been well elucidated yet; it can be a therapeutic target of immense importance in cancer drug research.

  • The varying expression profile of several important signalling molecules of inflammatory response like STAT’s, SOCS, etc. in case of macrophage skewing is still far from known.

  • A direct correlation between macrophage polarization and several inflammatory diseases is not well understood.

Reviewing the complete information about the two forms of macrophages and drawing a separating line between them to characterise each one of them including their relative gene expression can lay a foundation for the development of nucleus-targeted drugs which may be useful in treatment and prognosis of cancers that have a root cause in inflammation although, an extensive research needs to be done before reaching to any therapeutic conclusion.

References

  1. 1.
    Hume DA, Ross IL, Himes SR, Sasmono RT, Wells CA, Ravasi T. The mononuclear phagocyte system revisited. J Leukoc Biol. 2002;72:621–7.PubMedGoogle Scholar
  2. 2.
    Yona S, Kim K-W, Wolf Y, et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity. 2013;38:79–91.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Lefe`vr L, Gale`s A, Olagnier D, et al. PPARγ Ligands switched High Fat Diet-Induced Macrophage M2b polarization toward M2a Thereby Improving Intestinal Candida Elimination. PLoS ONE. 2010;9:e12828.CrossRefGoogle Scholar
  4. 4.
    Fujisaka S, Usui I, Bukhari A, et al. Regulatory mechanisms for adipose tissue M1 and M2 macrophages in diet-induced obese mice. Diabetes. 2009;58:2574–82.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007;117:175–84.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Chakkalath HR, Titus RG. Leishmania major-parasitized macrophages augment Th2-type T cell activation. J. Immunol. 1994;153:4378.PubMedGoogle Scholar
  7. 7.
    Andrew DC, Emma LB, John AH. The phenotype of inflammatory macrophages is stimulus dependent: implications for the nature of the inflammatory response. J Immunol. 2003;171:4816–23.CrossRefGoogle Scholar
  8. 8.
    Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005;5:953–64.PubMedCrossRefGoogle Scholar
  9. 9.
    Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003;3:23–35.PubMedCrossRefGoogle Scholar
  10. 10.
    Fernando M, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol. 2009;27:451–83.CrossRefGoogle Scholar
  11. 11.
    Mantovani A, Sozzani S, Locati M, et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23:549–55.PubMedCrossRefGoogle Scholar
  12. 12.
    Fernando M, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000prime Rep. 2014;6:13.Google Scholar
  13. 13.
    Mantovani A, Sica A, Sozzani S, et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25:677–86.PubMedCrossRefGoogle Scholar
  14. 14.
    Nathan CF, Jr Hibbs J B. Role of nitric oxide synthesis in macrophage antimicrobial activity. Curr Opin Immunol. 1991;3:65.PubMedCrossRefGoogle Scholar
  15. 15.
    Williams-Ashman HG, Canellakis ZN. Polyamines in mammalian biology and medicine. Perspect Biol Med. 1979;22:421.PubMedCrossRefGoogle Scholar
  16. 16.
    Wu G, Jr Morris S M. Arginine metabolism: nitric oxide and beyond. Biochem J. 1998;336:1.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Charles D. Mills, Kristi Kincaid, Jennifer M. M-1/M-2 Macrophages and the Th1/Th2 Paradigm. J Immunol. 2000;164:6166–73.CrossRefGoogle Scholar
  18. 18.
    Bourlier V, Girard AZ, Miranville A, et al. Remodeling phenotype of human subcutaneous adipose tissue macrophages. Circulation. 2008;117:806–15.PubMedCrossRefGoogle Scholar
  19. 19.
    Weisberg SP, Hunter D, Huber R, et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J. Clin. Invest. 2006;116:115–24.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, Riko K, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J. Clin. Invest. 2006;116:1494–505.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Kamei N, Tobe K, Suzuki R. Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem. 2006;281:26602–14.PubMedCrossRefGoogle Scholar
  22. 22.
    Ito A, Suganami T, Yamauchi A, et al. Role of CC chemokines receptor 2 in bone marrow cells in the recruitment of macrophages into obese adipose tissue. J Biol Chem. 2008;283:35715–23.PubMedCrossRefGoogle Scholar
  23. 23.
    Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science. 1993;259:87–91.PubMedCrossRefGoogle Scholar
  24. 24.
    Feinstein R, Kanety H, Papa MZ, et al. Tumor necrosis factor-α suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem. 1993;268:26055–8.PubMedGoogle Scholar
  25. 25.
    Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;307:426–30.PubMedCrossRefGoogle Scholar
  26. 26.
    Perreault M, Marette A. Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle. Nat Med. 2001;7:1138–43.PubMedCrossRefGoogle Scholar
  27. 27.
    Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity-and diet induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science. 2001;293:1673–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Pierce JW, Read MA, Ding H, et al. Salicylates inhibit I kappa B-alpha phosphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration. J. Immunol. 1996;156:3961–9.PubMedGoogle Scholar
  29. 29.
    Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β. Nature. 1998;396:77–80.PubMedCrossRefGoogle Scholar
  30. 30.
    Carey NL, Stephanie MDY, Jennifer LB, Alan RS. Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity. Diabetes. 2007;56:16–23.CrossRefGoogle Scholar
  31. 31.
    Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity induced insulin resistance in mice lacking TNF-alpha function. Nature. 1997;389:610–4.PubMedCrossRefGoogle Scholar
  32. 32.
    Mantovani Alberto. Inflammation and cancer: the macrophage connection. Medicina. 2007;67:32–4.Google Scholar
  33. 33.
    Geldhof AB, Van Ginderachter JA, Liu Y, Noël W, Raes G, De Baetselier P. Antagonistic effect of NK cells on alternatively activated monocytes: a contribution of NK cells to CTL generation. Blood. 2002;100(12):4049–58.PubMedCrossRefGoogle Scholar
  34. 34.
    Schutyser E, Struyf S, Proost P, et al. Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma. JBC. 2002;277:24584–93.CrossRefGoogle Scholar
  35. 35.
    Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009;9:239–52.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Bingle L, Brown NJ, Lewis CE. The role of tumor-associated macrophages in tumor progression: implications for new anticancer therapies. J Pathol. 2002;196:254–65.PubMedCrossRefGoogle Scholar
  37. 37.
    Jeffrey WP. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004;4:71–8.CrossRefGoogle Scholar
  38. 38.
    Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115–26.PubMedCrossRefGoogle Scholar
  39. 39.
    Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685–95.PubMedCrossRefGoogle Scholar
  40. 40.
    Bayes-Genis A, Conover CA, Overgaard MT, Bailey KR, Christiansen M, Jr Holmes D R, et al. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med. 2001;345:1022–9.PubMedCrossRefGoogle Scholar
  41. 41.
    Cooke JP, Oka RK. Does leptin cause vascular disease? Circulation. 2002;106:1904–5.PubMedCrossRefGoogle Scholar
  42. 42.
    Gurtner GC, Werner S, Barrandon Y, Longaker MT. Wound repair and regeneration. Nature. 2008;453:314–21.PubMedCrossRefGoogle Scholar
  43. 43.
    Redd MJ, Cooper L, Wood W, Stramer B, Martin P. Wound healing and inflammation: embryos reveal the way to perfect repair. Philos Trans R Soc Lond B Biol Sci. 2004;359:777–84.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Eming SA, Daniel AM, Ronald G, et al. Genetically modified human keratinocytes overexpressing PDGF-A enhance the performance of a composite skin graft. Hum Gene Ther. 1998;9(4):529–39.PubMedCrossRefGoogle Scholar
  45. 45.
    Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappa B. Nat Med. 2005;11:183–90.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Sinha S, Perdomo G, Brown NF, O’Doherty RM. Fatty acid-induced insulin resistance in L6 myotubes is prevented by inhibition of activation and nuclear localization of nuclear factor kappa B. J Biol Chem. 2004;279:41294–301.PubMedCrossRefGoogle Scholar
  47. 47.
    Monick MM, Robeff PK, Butler NS, et al. Phosphatidylinositol 3-kinase activity negatively regulates stability of cyclooxygenase 2 mRNA. J Biol Chem. 2002;277:32992.PubMedCrossRefGoogle Scholar
  48. 48.
    Sly LM, Ho V, Antignano F, et al. The role of SHIP in macrophages. Front Biosci. 2007;12:2836–48.PubMedCrossRefGoogle Scholar
  49. 49.
    Tzameli I, Fang H, Ollero M, et al. Regulated production of a peroxisome proliferator-activated receptor-gamma ligand during an early phase of adipocyte differentiation in 3T3-L1 adipocytes. J Biol Chem. 2004;279:36093–102.PubMedCrossRefGoogle Scholar
  50. 50.
    Ho VW, Sly LM. Derivation and characterization of murine alternatively activated (M2) macrophages. Methods Mol Biol. 2009;531:173–85.PubMedCrossRefGoogle Scholar
  51. 51.
    Straus DS, Glass CK. Anti-inflammatory actions of PPAR ligands: new Insights on cellular and molecular mechanisms. Trends Immunol. 2007;28:551–8.PubMedCrossRefGoogle Scholar
  52. 52.
    Eibl G. The role of PPAR-γ and its interactions with COX-2 in pancreatic cancer. PPAR research. 2008;2008:326915.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Han YP, Tuan TL, Wu H, et al. TNF-alpha stimulates activation of pro-MMP2 in human skin through NF-(kappa) B mediated induction of MT1-MMP. J Cell Sci. 2001;114:131–9.PubMedPubMedCentralGoogle Scholar
  54. 54.
    Iwaki M, Matsuda M, Maeda N, et al. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes. 2003;52:1655–63.PubMedCrossRefGoogle Scholar
  55. 55.
    Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol. 2009;27:693–733.PubMedCrossRefGoogle Scholar
  56. 56.
    Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat Rev Immunol. 2002;2:725–34.PubMedCrossRefGoogle Scholar
  57. 57.
    Cavaillon JM, Adib-Conquy M. Bench-to-bedside review: endotoxin tolerance as a model of leukocyte reprogramming in sepsis. Crit Care. 2006;10:233.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Porta C, Rimoldi M, Raes G, et al. Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor κB. PNAS. 2008;106(35):14978–83.CrossRefGoogle Scholar
  59. 59.
    Zhang Z, Li X, Lv W, et al. Ginsenoside Re Reduces Insulin Resistance through Inhibition of c-Jun NH2-Terminal Kinase and Nuclear Factor- Κb. Mol Endocrinol. 2008;22:186–95.PubMedCrossRefGoogle Scholar
  60. 60.
    Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. Clin Invest. 2003;112:1796–808.CrossRefGoogle Scholar
  61. 61.
    Ferrante AW Jr. Obesity-induced inflammation: a metabolic dialogue in the language of inflammation. J Intern Med. 2007;262:408–14.PubMedCrossRefGoogle Scholar
  62. 62.
    Fong CHY, Didierlaurent A, et al. An antiinflammatory role for IKKβ through the inhibition of “classical” macrophage activation. J Exp Med. 2008;205(6):1269–76.PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Powell DJ, Turban S, Gray A, et al. Intracellular ceramide synthesis and protein kinase Cζ activation play an essential role in palmitate-induced insulin resistance in rat L6 skeletal muscle cells. Biochem J. 2004;382:619–29.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Sabin MA, Stewart CE, Crowne EC, et al. Fatty acid-induced defects in insulin signalling, in myotubes derived from children, are related to ceramide production from palmitate rather than the accumulation of intra myocellular lipid. J Cell Physiol. 2007;211:244–52.PubMedCrossRefGoogle Scholar
  65. 65.
    Jove M, Planavila A, Laguna JC, Vazquez-Carrera M. Palmitate induced interleukin 6 production is mediated by protein kinase C and nuclear-factor kB activation and leads to glucose transporter 4 down-regulation in skeletal muscle cells. Endocrinology. 2005;146:3087–95.PubMedCrossRefGoogle Scholar
  66. 66.
    Jove M, Planavila A, Sanchez RM, et al. Palmitate induce tumor necrosis factor-a expression in C2C12 skeletal muscle cells by a mechanism involving protein kinase C and nuclear factor-kB activation. Endocrinology. 2006;147:552–61.PubMedCrossRefGoogle Scholar
  67. 67.
    Weigert C, Brodbeck K, Staiger H, Kaush C, Machicao F, Haring H, et al. Palmitate, but not unsaturated fatty acids, induces the expression of interleukin-6 in human myotubes through proteosomedependent activation of nuclear factor-kB. J Biol Chem. 2004;279:23942–52.PubMedCrossRefGoogle Scholar
  68. 68.
    Perkins ND. Oncogenes, tumor suppressors and p52 NF-kB. Oncogene. 2003;22:7553–6.PubMedCrossRefGoogle Scholar
  69. 69.
    Kieran M, Blank V, Logeat F, et al. The DNA binding subunit of NF-kB is identical to factor KBF1 and homologous to the rel oncogene product. Cell. 1990;62:1007–18.PubMedCrossRefGoogle Scholar
  70. 70.
    Ghosh S, Gifford AM, Riviere LR, et al. Cloning of the p50 DNA binding subunit of NF-kB: homology to rel and dorsal. Cell. 1990;62:1019–29.PubMedCrossRefGoogle Scholar
  71. 71.
    Gilmore TD. Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel. Oncogene. 1999;18:6925–37.PubMedCrossRefGoogle Scholar
  72. 72.
    Perkins ND. NF-κB: tumor promoter or suppressor? Trends Cell Biol. 2004;14:64–9.PubMedCrossRefGoogle Scholar
  73. 73.
    Pahl HL. Activators and target genes of Rel/NF-kB transcription factors. Oncogene. 1999;18:6853–66.PubMedCrossRefGoogle Scholar
  74. 74.
    Ryan KM, Ernst MK, Rice NR, Vousden KH. Role of NF-kB in p53-mediated programmed cell death. Nature. 2000;404:892–7.PubMedCrossRefGoogle Scholar
  75. 75.
    Rocha S, Campbell KJ, Perkins ND. p53 andMdM2 independent repression of NF-kB transactivation by the ARF tumour suppressor. Mol Cell. 2003;12:15–25.PubMedCrossRefGoogle Scholar
  76. 76.
    Rauh MJ, Sly LM, Kalesnikoff J, et al. The role of SHIP1 in macrophage programming and activation. Biochem Soc Trans. 2004;32:5.CrossRefGoogle Scholar
  77. 77.
    Sly LM, Rauh MJ, Kalesnikoff J, et al. SHIP, SHIP2, and PTEN activities are regulated in vivo by modulation of their protein levels: SHIP is up-regulated in macrophages and mast cells by lipopolysaccharide. Exp Hematol. 2003;31:1170–81.PubMedCrossRefGoogle Scholar
  78. 78.
    Maxwell MJ, Yuan Y, Anderson KE, et al. SHIP-1 and lyn kinase negatively regulate integrin alpha IIb beta3 signaling in platelets. J Biol Chem. 2004;279:32196–204.PubMedCrossRefGoogle Scholar
  79. 79.
    Kalesnikoff J, Lam V, Krystal G. SHIP represses mast cell activation and reveals that IgE alone triggers signaling pathways which enhance normal mast cell survival. Mol Immunol. 2002;38:1201–6.PubMedCrossRefGoogle Scholar
  80. 80.
    Lam V, Kalesnikoff J, Lee CW, Hernandez-Hansen V, et al. IgE alone stimulates mast cell adhesion to fibronectin via pathways similar to those used by IgE + antigen but distinct from those used by Steel factor. Blood. 2003;102:1405–13.PubMedCrossRefGoogle Scholar
  81. 81.
    Giuriato S, Pesesse X, Bodin S, et al. SH2-containing inositol 5-phosphatases 1 and 2 in blood platelets: their interactions and roes in the control of phosphatidylinositol 3,4,5-trisphosphate levels. Biochem J. 2003;376:199–207.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Gardai S, Whitlock BB, Helgason C, et al. Activation of SHIP by NADPH oxidase-stimulated Lyn leads to enhanced apoptosis in neutrophils. J Biol Chem. 2002;277:5236–46.PubMedCrossRefGoogle Scholar
  83. 83.
    Fibach E. Involvement of phosphatases in proliferation, maturation, and hemoglobinization of developing erythroid cells. J Signal Transduc. 2011;2011:860985.CrossRefGoogle Scholar
  84. 84.
    Sly LM, Rauh MJ, Kalesnikoff J, et al. LPS-induced upregulation of SHIP is essential for endotoxin tolerance. Immunity. 2004;21:227–39.PubMedCrossRefGoogle Scholar
  85. 85.
    Guha M, Mackman N. The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. J Biol Chem. 2002;277:32124.PubMedCrossRefGoogle Scholar
  86. 86.
    Huang XL, Wang YJ, Yan JW, et al. Role of anti-inflammatory cytokines IL-4 and IL-13 in systemicsclerosis Inflamm. Res. 2015;64:151–9.Google Scholar
  87. 87.
    Rauh MJ, Ho V, Pereira C, et al. SHIP represses the generation of alternatively activated macrophages. Immunity. 2005;23:361–74.PubMedCrossRefGoogle Scholar
  88. 88.
    Hamilton MJ, Ho VW, Kuroda E, et al. Role of SHIP in cancer. Exp Hematol. 2011;39:2–3.PubMedCrossRefGoogle Scholar
  89. 89.
    Jiang BH, Liu LZ. PI3 K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res. 2009;102:19–65.PubMedPubMedCentralCrossRefGoogle Scholar
  90. 90.
    Ho VW, Hamilton MJ, Kuroda E, et al. Tumour-associated macrophages. Biomed Life Sci. 2012;3:135–51.Google Scholar
  91. 91.
    Costinean S, Sandhu SK, Pedersen IM, et al. Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein beta are targeted by miR-155 in B cells of Emicro-MiR-155 transgenic mice. Blood. 2009;114:1374–82.PubMedPubMedCentralCrossRefGoogle Scholar
  92. 92.
    Lo TC, Barnhill LM, Kim Y, et al. Inactivation of SHIP1 in T-cell acute lymphoblastic leukemia due to mutation and extensive alternative splicing. Leuk. 2009;33:1562–6.CrossRefGoogle Scholar
  93. 93.
    O’Connell RM, Chaudhuri AA, Rao DS, Baltimore D. Inositol phosphatase SHIP1 is a primary target of miR-155. Proc Natl Acad Sci USA. 2009;106:7113–8.PubMedPubMedCentralCrossRefGoogle Scholar
  94. 94.
    Pedersen IM, Otero D, Kao E, et al. Onco-miR-155 targets SHIP1 to promote TNFα-dependent growth of B cell lymphomas. EMBO Mol Med. 2009;1:288–95.PubMedPubMedCentralCrossRefGoogle Scholar
  95. 95.
    Yamanaka Y, Tagawa H, Takahashi N, et al. Aberrant overexpression of microRNAs activate AKT signaling via down-regulation of tumor suppressors in natural killer-cell lymphoma/leukemia. Blood. 2009;114:3265–75.PubMedCrossRefGoogle Scholar
  96. 96.
    Marx N, Bourcier T, Sukhova G, et al. PPARg activation in human endothelial cells increases plasminogen activator inhibitor type-I expression. Arterioscler Thromb Vasc Biol. 1999;19:546–51.PubMedCrossRefGoogle Scholar
  97. 97.
    Inoue I, Shino K, Noji S, et al. Expression of peroxisome proliferator-activated receptor a (PPARa) in primary cultures of human vascular endothelial cells. Biochem Biophys Res Commun. 1998;246:370–4.PubMedCrossRefGoogle Scholar
  98. 98.
    Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 1990;347:645–50.PubMedCrossRefGoogle Scholar
  99. 99.
    Fajas L, Auboeuf D, Raspé E, et al. The organization, promoter analysis, and expression of the human PPAR gamma gene. J Biol Chem. 1997;272(18):779–89.Google Scholar
  100. 100.
    Hevener AL, Olefsky JM, Reichart D, et al. Macrophage PPARγ is required for normal skeletal muscle and hepatic insulin sensitivity and full anti-diabetic effects of thiazolidinediones. J Clin Investig. 2007;117:1658–69.PubMedPubMedCentralCrossRefGoogle Scholar
  101. 101.
    Kliewer SA, Umesono K, Noonan DJ, et al. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature. 1992;358:771–4.PubMedCrossRefGoogle Scholar
  102. 102.
    Kliewer SA, Sundseth SS, Jones SA, et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci USA. 1997;94:4318–23.PubMedPubMedCentralCrossRefGoogle Scholar
  103. 103.
    McIntyre TM, Pontsler AV, Silva AR, et al. Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPAR gamma agonist. Proc Natl Acad Sci USA. 2003;100:131–6.PubMedPubMedCentralCrossRefGoogle Scholar
  104. 104.
    Ricote M, Li AC, Willson TM, et al. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 1998;391:79–82.PubMedCrossRefGoogle Scholar
  105. 105.
    Lazar MA. PPAR gamma, 10 years later. Biochimie. 2005;87:9–13.PubMedCrossRefGoogle Scholar
  106. 106.
    Han KH, Chang MK, Boullier A, et al. Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator activated receptor-ϒ. J Clin Invest. 2000;106:793–802.PubMedPubMedCentralCrossRefGoogle Scholar
  107. 107.
    Barlic J, Zhang Y, Foley JF, Murphy PM. Oxidized lipid-driven chemokine receptor switch, CCR2 to CX3CR1, mediates adhesion of human macrophages to coronary artery smooth muscle cells through a peroxisome proliferator-activated receptor gamma-dependent pathway. Circulation. 2006;114:807–19.PubMedCrossRefGoogle Scholar
  108. 108.
    Chawla A, Barak Y, Nagy L, et al. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med. 2001;7:48–52.PubMedCrossRefGoogle Scholar
  109. 109.
    Spiegelman BM. PPAR-γ Adipogenic Regulator and Thiazolidinedione Receptor. Diabetes. 1998;47:507–14.PubMedCrossRefGoogle Scholar
  110. 110.
    Nagai S, Shimizu C, Taniguchi UMS, et al. Identification of a function peroxisome proliferator-activated receptor responsive element within the murine perilipin gene. Endocrinology. 2004;145:2346–56.PubMedCrossRefGoogle Scholar
  111. 111.
    Guan HP, Ishizuka T, Chui PC, et al. Corepressors selectively control the transcriptional activity of PPAR gamma in adipocytes. Genes Dev. 2005;19:453–61.PubMedPubMedCentralCrossRefGoogle Scholar
  112. 112.
    Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, et al. Macrophage-specific PPAR gamma controls alternative activation and improves insulin resistance. Nature. 2007;447:1116–20.PubMedPubMedCentralCrossRefGoogle Scholar
  113. 113.
    Pascual G, Glass CK. Nuclear receptors versus inflammation: mechanisms of transrepression. Trends Endocrinol Metab. 2006;17:321–7.PubMedCrossRefGoogle Scholar
  114. 114.
    Yerly-Motta V, Contassot E, Pavy JJ, et al. Expression of cyclins and cdks throughout murine carcinogenesis Cell. Mol Biol. 1999;45:1217–28.Google Scholar
  115. 115.
    Peters JM, Aoyama T, Cattley RC, et al. Role of peroxisome proliferator-activated receptor alpha in altered cell cycle regulation in mouse liver. Carcinogenesis. 1998;19:1989–94.PubMedCrossRefGoogle Scholar
  116. 116.
    Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell. 1996;87:803.PubMedCrossRefGoogle Scholar
  117. 117.
    Saez E, Tontonoz P, Nelson MC, et al. Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med. 1998;4:1058–61.PubMedCrossRefGoogle Scholar
  118. 118.
    Sarraf P, Mueller E, Jones D, et al. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med. 1998;4:1046–52.PubMedCrossRefGoogle Scholar
  119. 119.
    Friedmann PS, Cooper HL, Healy E. Peroxisome proliferator-activated receptors and their relevance to dermatology. Acta Derm Venereol. 2005;85:194–202.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Basel 2015

Authors and Affiliations

  • Samina Bashir
    • 1
  • Yadhu Sharma
    • 1
  • Asif Elahi
    • 1
  • Farah Khan
    • 1
  1. 1.Department of Biochemistry, Faculty of ScienceJamia Hamdard UniversityNew DelhiIndia

Personalised recommendations